Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
3.060
-0.090 (-2.86%)
Feb 20, 2026, 4:00 PM EST - Market closed
Protalix BioTherapeutics Employees
Protalix BioTherapeutics had 213 employees as of December 31, 2024. The number of employees increased by 5 or 2.40% compared to the previous year.
Employees
213
Change (1Y)
5
Growth (1Y)
2.40%
Revenue / Employee
$290,329
Profits / Employee
$25,324
Market Cap
246.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 213 | 5 | 2.40% | 213 | 0 |
| Dec 31, 2023 | 208 | 11 | 5.58% | 208 | 0 |
| Dec 31, 2022 | 197 | -9 | -4.37% | 193 | 4 |
| Dec 31, 2021 | 206 | -1 | -0.48% | 202 | 4 |
| Dec 31, 2020 | 207 | 11 | 5.61% | 207 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 158 |
| Silence Therapeutics | 116 |
| OmniAb | 114 |
| Orchestra BioMed Holdings | 70 |
| Larimar Therapeutics | 65 |
| Shattuck Labs | 44 |
| Sol-Gel Technologies | 34 |
| Achieve Life Sciences | 25 |
PLX News
- 19 days ago - A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
- 22 days ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - GlobeNewsWire
- 22 days ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewsWire
- 6 weeks ago - Protalix BioTherapeutics Letter to Stockholders - PRNewsWire
- 2 months ago - Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - PRNewsWire
- 3 months ago - Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results - PRNewsWire
- 3 months ago - Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - PRNewsWire